Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Clene ( (CLNN) ).
Clene, a company involved in developing treatments for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has outlined a potential path for accelerated approval of its CNM-Au8 treatment in ALS through additional biomarker data submission. This development could significantly impact Clene’s operations by potentially speeding up the approval process, enhancing its market position in the neurodegenerative treatment industry, and providing a promising option for stakeholders invested in ALS treatments.
More about Clene
YTD Price Performance: -19.93%
Average Trading Volume: 78,263
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $37.9M
For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.